- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
is a division of
Albireo Appoints Dr Hans Graffner as Chief Medical Officer
—
GOTHENBURG, Sweden, May 15GOTHENBURG, Sweden, May 15 /PRNewswire/ -- Albireo, a pharmaceutical company focusing on the development of therapeutics for gastrointestinal diseases, announced today the appointment of Hans Graffner, M.D., Ph.D, as Chief Medical Officer (CMO).
Dr. Graffner will oversee the clinical development programs at Albireo with initial focus on the lead program A3309, a therapeutic with a novel mechanism of action targeting the treatment of patients with chronic constipation.
Dr. Graffner comes to Albireo with over 12 years experience of leading clinical development programs in the pharmaceutical industry. Most recently, Dr. Graffner was the Senior Medical Director at Merck Serono, leading clinical development of products mainly in the areas of autoimmune diseases, including inflammatory bowel diseases. Dr. Graffner has an impressive track record of success, bringing Entocort (budesonide) and Colazide (balsalazide) through registration and bringing Nexium to market at AstraZeneca.
Dr. David Chiswell, Executive Chairman of the Albireo Board of Directors, said: "We are delighted to have been able to attract Hans to Albireo as our CMO. His extensive and impressive experience in bringing products from early clinical development to the market within the gastrointestinal area will be of great value for the clinical development of our lead program A3309 as well as future development programs."
About Albireo
Albireo is a Swedish biotechnology company with broad experience in the GI area and a pipeline of programmes for underserved markets. Spun off from AstraZeneca in February 2008, the Albireo team has extensive links to industry and academia, as well as key scientific and clinical communities. Albireo is focused on developing novel therapies that address unmet medical needs in the GI area. Albireo is based in Gothenburg, Sweden. For more information please visit http://www.albireopharma.com
Related news
Related News
- Albireo Announces Second Closing of Series A Financing
- Nventa Appoints John Varian to Board of Directors
- Mentice Appoints Bj
- Synosia Therapeutics Appoints Chief Financial Officer to New Company Headquarters in Switzerland
- Nventa Appoints Gordon H. Busenbark to Board of Directors
- Stiefel Laboratories Appoints First Chief Scientific Officer
- Kendle Appoints Patricia Williams Vice President, Commercial Operations
- Nucletron Appoints New Chief Executive Officer
- Quintiles Appoints Oren Cohen to Senior Vice President, Clinical Research Strategies
- UltraShape Appoints Assaf Eyal as President & CEO
Latest News
- The Future of Financing Health Services in Africa
- Unique Digital Breast Screening Part of Offering by New Clinic
- Canada Supports Ground-Breaking Malaria Treatment Program in Sub-Saharan Africa
- Unite's NHS Members Hold Day of Action on Wednesday, 3 December Over Pay
- Beat the Credit Crunch This Christmas With High Quality American Peanuts!
- Dynamics Group AG Publishes Research Report on Senetek
- diaDexus Receives CE Mark Certification for the PLAC(R) Test
- Improving Occupational Safety and Health Worldwide
- German Innovation for HIV/AIDS Diagnostics Has Been Used 2.5 Million Times in 2008
- Elsevier's EMBASE.com Partners With QUOSA
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us